Bahmanyar, M, Fayaz, A, Nour-Salehi, S, Mohammadi, M, Koprowski, H. Successful protection of humans exposed to rabies infection: postexposure treatment with the new human diploid cell rabies vaccine and antirabies serum. JAMA 1976;236:2751-4.
Corey, L, Hattwick, MAW. Treatment of persons exposed to rabies. JAMA 1975;232:272-6.
Greenberg, M, Childress, J. Vaccination against rabies with duck embryo and Semple vaccine. JAMA 1960;173:333-7.
Hattwick, MAW. Human rabies. Public Health Reviews 1974;2:229-75.
Hattwick, MAW, Rubin, RH, Music, S, Sikes, RK, Smith, JS, Gregg, MB. Postexposure rabies prophylaxis with human rabies immune globulin. JAMA 1974;227:407-10.
Johnson, HN. Rabies virus. In: Horsfall, FL, Tamm, I, eds. Viral and rickettsial infections of man, 4th ed. Philadelphia: JB Lippincott, 1965;814-40.
Peck, FM Jr, Powell, HM, Culbertson, CG. A new antirabies vaccine for human use. J Lab Clin Med 1955;45:679-83.
Rubin, RH, Hattwick, MAW, Jones, S, Gregg, MB, Schwartz, VD. Adverse reactions to duck embryo rabies vaccine; range and incidence. Ann Intern Med 1973;78:643-49.
Tierkel, ES, Sikes, RK: Preexposure prophylaxis against rabies: comparison of regimens. JAMA 1967;201:911-14.
Tint, H, Rosanoff, EI. Clinical responses to T(N) BP — disrupted HDCS (WI-38) rabies vaccine. Dev Biol Stand 1977;37:287-9.
Wiktor, TJ, Plotkin, SA, Koprowski, H. Development and clinical trials of the new human rabies vaccine of tissue culture (human diploid cell) origin. Dev Biol Stand 1978;40:3–9.
World Health Organization. Sixth report of the Expert Committee on Rabies. Geneva, Switzerland: World Health Organization, 1973. (WHO Tech Rep No. 523).
Working Group 2, World Health Organization. Vaccine potency requirements for reduced immunization schedules and pre-exposure treatment. Dev Biol Stand 1978;40:268-70.
Anderson, LJ, Sikes, RK, Langkop, CW, et al. Postexposure trial of a human diploid cell strain rabies vaccine. J Infect Dis (in press).